RVL Pharmaceuticals plc (NASDAQ:RVLP – Get Rating) – Analysts at Jefferies Financial Group decreased their FY2025 earnings per share (EPS) estimates for shares of RVL Pharmaceuticals in a research report issued on Monday, January 9th. Jefferies Financial Group analyst G. Santangelo now forecasts that the company will earn $0.00 per share for the year, down from their prior estimate of $0.01. Jefferies Financial Group has a "Hold" rating and a $2.50 price objective on the stock. The consensus estimate for RVL Pharmaceuticals' current full-year earnings is ($0.66) per share. Jefferies Financial Group also issued estimates for RVL Pharmaceuticals' FY2026 earnings at $0.13 EPS.

RVL Pharmaceuticals (NASDAQ:RVLP – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.03. RVL Pharmaceuticals had a negative return on equity of 92.27% and a negative net margin of 124.13%. The company had revenue of $10.02 million for the quarter, compared to analyst estimates of $10.05 million.

RVL Pharmaceuticals Price Performance

Shares of RVL Pharmaceuticals stock opened at $1.26 on Thursday. The company has a quick ratio of 3.27, a current ratio of 3.30 and a debt-to-equity ratio of 0.82. The firm has a market cap of $124.93 million, a P/E ratio of -2.03 and a beta of 1.17. RVL Pharmaceuticals has a fifty-two week low of $0.99 and a fifty-two week high of $2.99. The business has a 50-day moving average price of $1.33 and a 200 day moving average price of $1.71.

Institutional Trading of RVL Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Marietta Wealth Management LLC acquired a new position in RVL Pharmaceuticals in the second quarter valued at approximately $163,000. Insight Advisors LLC PA acquired a new position in RVL Pharmaceuticals in the second quarter valued at approximately $59,000. Northern Trust Corp acquired a new position in RVL Pharmaceuticals in the second quarter valued at approximately $97,000. Renaissance Technologies LLC acquired a new position in RVL Pharmaceuticals in the second quarter valued at approximately $1,143,000. Finally, Atria Wealth Solutions Inc. acquired a new position in RVL Pharmaceuticals in the second quarter valued at approximately $37,000. 62.91% of the stock is owned by institutional investors.

RVL Pharmaceuticals Company Profile

(Get Rating)

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults.

Recommended Stories

• Get a free copy of the StockNews.com research report on RVL Pharmaceuticals (RVLP)
• Optimism About Global Demand For Metals Boosts BHP, Other Miners
• Exxon Mobil Expects Earnings and Cash Flow to Grow
• Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
• Is The Great Alibaba Recovery About To Begin?
• KB Home, Another Reason To Shed Home Building Stocks

Receive News & Ratings for RVL Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RVL Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.